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C a se  r e p or t
A 65-year-old man was diagnosed with metastatic clear 
cell renal cell carcinoma with sarcomatoid differentiation. 
Within weeks after a palliative nephrectomy, the patient’s 
condition deteriorated. Computed tomography (CT) 
scan showed progressive disease of the pulmonary 
metastases (panel A) and we started treatment with the 
oral angiogenesis inhibitor sunitinib 50 mg once daily, 
4 weeks on, 2 weeks off. Sunitinib is a multiple tyrosine 
kinase inhibitor targeting the vascular endothelial growth 
factor receptor, platelet derived growth factor receptor, 
c-kit, neurotrophic factor receptor RET and FMS-like 
tyrosine kinase 3. Three weeks after starting treatment, 
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the patient presented at the emergency ward with right 
thoracic pain, dyspnoea and cough. Laboratory studies 
showed a haemoglobin of 6.2 mmol/l (was 6.1 mmol/l 
5 days before), leucocytes of 7.3 x 109/l (was 9.7 x 109/l 5 
days before), C-reactive protein 176 mg/l (was 144 mg/l 9 
days before) and a D-dimer of 6234 ng/ml. A new CT was 
performed (panel B).
what  i s  you r  d i agno s i s ?
See page 232 for the answer to this photo quiz.
figure 1. 
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d i agnos i s
The differential diagnosis of thoracic pain in this 
patient included a pulmonary embolus, pneumonia, 
pneumothorax, pleural effusion, and pleural metastases 
or bleeding within a metastasis. An angiographic CT scan 
excluded a pulmonary embolus and showed no signs of 
pneumonia, pneumothorax or pleural effusions. However, 
the CT scan showed extensive central necrosis of the lung 
metastases with cavitation (panel B), of which the largest 
was located in the area of the patient’s pain. The CT image 
is characteristic for a good response of metastases of renal 
cell carcinoma to antiangiogenic treatment, although the 
size of the metastases did not decrease. 
For the evaluation of treatment response of cancer, the 
Response Evaluation Criteria in Solid Tumours (RECIST) 
are used.1 RECIST is based on the sum of one-dimensional 
measurements of the greatest diameter of the tumour 
and/or metastases. In the presented patient, according to 
RECIST, stable disease (+9%) was established. However, the 
sunitinib-induced extensive necrosis and cavitation illustrate 
the limitations of the RECIST guidelines for the evaluation 
of response to targeted therapies. The effect of targeted 
therapies as angiogenesis inhibitors and antivascular drugs 
can be underestimated by using the tumour size based 
RECIST guidelines.2 In case of first-line treatment with 
sunitinib in RCC patients, the observed objective response 
rate is 47%, with a progression-free survival of 11 months, 
compared with five months for interferon alpha.3 However, 
first-line single-agent treatment with sorafenib4 in metastatic 
renal cell cancer failed to achieve significant objective 
response rates according to the RECIST criteria, but did 
result in a significant increase in progression-free survival, 
demonstrating its clinical efficacy.
Attempts are made to achieve more sophisticated imaging 
techniques or evaluation criteria. Striking examples are the 
PET criteria, also called PERCIST.5 and the Choi criteria 
for gastrointestinal stromal tumours (GIST).6 The Choi 
criteria add tumour density to tumour size, which makes 
it possible to assess tumour necrosis, an early feature of 
antiangiogenic therapies. 
In this patient, the sunitinib was continued and analgesics 
were added. After this episode the condition of the patient 
gradually improved, the cough and pain disappeared and 
his weight increased. Unfortunately, five months later he 
developed cerebral metastases and died shortly thereafter.
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